Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of collection and transport conditions for autologous bone marrow mesenchymal stem cells in spinal cord injury
jRCT1010220039Recruiting
- Sponsor
- Masanori Sasaki
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of milciclib in spinal cord injury (SCI), sponsored by Masanori Sasaki. Primary endpoint: cell collection rate. Started Feb 2023; status: recruiting.
02
Drugs
milciclib
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT1010220039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1010220039.